Filtern
Volltext vorhanden
- ja (9)
Gehört zur Bibliographie
- ja (9)
Dokumenttyp
Sprache
- Englisch (9) (entfernen)
Schlagworte
- cytotoxic T cells (2)
- regulatory T cells (2)
- signal transduction (2)
- ADP-ribosylation toxins (1)
- Activation induced cell death/AICD (1)
- Alpha therapy (1)
- Anergy (1)
- Apoptosis (1)
- Autoimmune diseases (1)
- Bone marrow transplantantation (1)
Institut
- Pathologisches Institut (5)
- Institut für Systemimmunologie (3)
- Institut für Virologie und Immunbiologie (3)
- Medizinische Klinik und Poliklinik II (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für Experimentelle Biomedizin (1)
- Julius-von-Sachs-Institut für Biowissenschaften (1)
Donor CD4\(^+\)Foxp3\(^+\) regulatory T cells (T reg cells) suppress graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HCT allo-HCT]). Current clinical study protocols rely on the ex vivo expansion of donor T reg cells and their infusion in high numbers. In this study, we present a novel strategy for inhibiting GvHD that is based on the in vivo expansion of recipient T reg cells before allo-HCT, exploiting the crucial role of tumor necrosis factor receptor 2 (TNFR2) in T reg cell biology. Expanding radiation-resistant host T reg cells in recipient mice using a mouse TNFR2-selective agonist before allo-HCT significantly prolonged survival and reduced GvHD severity in a TNFR2-and T reg cell-dependent manner. The beneficial effects of transplanted T cells against leukemia cells and infectious pathogens remained unaffected. A corresponding human TNFR2-specific agonist expanded human T reg cells in vitro. These observations indicate the potential of our strategy to protect allo-HCT patients from acute GvHD by expanding T reg cells via selective TNFR2 activation in vivo.